Myriad Genetics 

$4.66
10
-$0.19-3.92% Friday 19:59

Statistics

Day High
4.9
Day Low
4.62
52W High
10.32
52W Low
3.76
Volume
1,704,067
Avg. Volume
1,280,606
Mkt Cap
435.75M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30AprExpected
Q3 2024
Q4 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.07
-0.03
0.02
0.06
Expected EPS
-0.068331
Actual EPS
N/A

Financials

-44.38%Profit Margin
Unprofitable
2020
2021
2022
2023
2024
2025
1.65BRevenue
-731.8MNet Income

Analyst Ratings

$7.38Average Price Target
The highest estimate is 9.00.
From 4 ratings within the last 6 months. This is not an investment recommendation.
Buy
25%
Hold
75%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow MYGN. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Illumina
ILMN
Mkt Cap18.99B
Illumina provides genomic sequencing solutions and competes directly in the genetic testing market, overlapping with Myriad's cancer and other disease-related genetic tests.
Guardant Health
GH
Mkt Cap11.72B
Guardant Health specializes in liquid biopsies and cancer diagnostics, directly competing with Myriad's cancer genetic tests.
Exact Sciences
EXAS
Mkt Cap12.25B
Exact Sciences offers cancer screening and diagnostic tests, including Cologuard, competing in the oncology diagnostics space with Myriad.
Fulgent Genetics
FLGT
Mkt Cap687.17M
Fulgent Genetics provides comprehensive genetic testing services, competing with Myriad in the space of personalized medicine and genetic diagnostics.
Qiagen NV
QGEN
Mkt Cap10.16B
Qiagen offers sample and assay technologies for molecular diagnostics, applied testing, academic and pharmaceutical research, competing in the genetic testing market.
Bionano Genomics
BNGO
Mkt Cap17.42M
Bionano Genomics focuses on genomic analysis and offers services that compete with Myriad's genetic testing and analysis services.
Pacific Biosciences of California
PACB
Mkt Cap702.87M
Pacific Biosciences offers sequencing systems that compete with Myriad's genetic testing technologies, especially in comprehensive genomic profiling.
Thermo Fisher Scientific
TMO
Mkt Cap214.25B
Thermo Fisher Scientific offers a wide range of services and products for genetic analysis and diagnostics, competing with Myriad in the life sciences and healthcare sectors.
Quest Diagnostics
DGX
Mkt Cap19.57B
Quest Diagnostics provides diagnostic testing, information, and services, including genetic testing, competing with Myriad in the broader diagnostics market.

About

Myriad Genetics, Inc., a molecular diagnostic testing and precision medicine company, develops and provides molecular tests. The company offers molecular diagnostic tests for oncology, women's health, and pharmacogenomics. It also provides MyRisk Hereditary Cancer test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic test, a DNA sequencing test to help determine the therapy for metastatic breast, ovarian, metastatic pancreatic, and metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. In addition, the company offers Prolaris Prostate Cancer Prognostic test, an RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic test, an RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor Molecular Profile test, a genomic profiling test; Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus; Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; SneakPeek Early Gender DNA test, a non-invasive blood test that predicts the gender of a fetus; and GeneSight Psychotropic Mental Health Medication test, a DNA genotyping test to aid psychotropic drug selection for depression, anxiety, attention-deficit/hyperactivity disorder, and other mental health conditions. It has a license collaboration with Illumina, Inc.; Memorial Sloan Kettering Cancer Center; the University of Texas MD Anderson Cancer Center; the University of Rochester Medical Center; and Flatiron Health, Inc. The company has a strategic alliance with SOPHiA GENETICS SA for the development of liquid biopsy companion diagnostic (CDx) test. The co
Show more...
CEO
Mr. Samraat S. Raha
Employees
2700
Country
US
ISIN
US62855J1043

Listings

0 Comments

Share your thoughts

FAQ

What is Myriad Genetics stock price today?
The current price of MYGN is $4.66 USD — it has decreased by -3.92% in the past 24 hours. Watch Myriad Genetics stock price performance more closely on the chart.
What is Myriad Genetics stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on exchange Myriad Genetics stocks are traded under the ticker MYGN.
Is Myriad Genetics stock price growing?
MYGN stock has fallen by -3.12% compared to the previous week, the month change is a +3.79% rise, over the last year Myriad Genetics has showed a -53.72% decrease.
What is Myriad Genetics market cap?
Today Myriad Genetics has the market capitalization of 435.75M
When is the next Myriad Genetics earnings date?
Myriad Genetics is going to release the next earnings report on April 30, 2026.
What were Myriad Genetics earnings last quarter?
MYGN earnings for the last quarter are 0.04 USD per share, whereas the estimation was -0.01 USD resulting in a +367.97% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Myriad Genetics revenue for the last year?
Myriad Genetics revenue for the last year amounts to 1.65B USD.
What is Myriad Genetics net income for the last year?
MYGN net income for the last year is -731.8M USD.
How many employees does Myriad Genetics have?
As of March 16, 2026, the company has 2,700 employees.
In which sector is Myriad Genetics located?
Myriad Genetics operates in the Health Care sector.
When did Myriad Genetics complete a stock split?
The last stock split for Myriad Genetics was on March 26, 2009 with a ratio of 2:1.
Where is Myriad Genetics headquartered?
Myriad Genetics is headquartered in Salt Lake City, US.